Locally acting therapies are like a religion to Flexion Therapeutics (NSDQ:FLXN) co-founder & CEO Dr. Mike Clayman, who spent decades at Eli Lilly (NYSE:LLY) with the company’s co-founder, Dr. Neil Bodick, watching promising compounds fail in late-stage trials on the heels of unanticipated safety results. “That’s part of the reason, not the whole reason but part of […]
Eli Lilly & Co.
Dexcom inks continuous glucose monitoring deal with UnitedHealth
Shares in Dexcom (NSDQ:DXCM) rose 4% today after the company announced a partnership with UnitedHealth (NYSE:UNH) to assess if data from a continuous glucose monitor can help people with Type II diabetes manage their condition in a cost-effective way. UnitedHealth is slated to use CGM data, as well as diet and exercise activity, in a study […]
Kala Pharmaceuticals taps biopharma exec as chief operating officer | Personnel Moves – Nov. 27, 2017
Kala Pharmaceuticals (NSDQ:KALA) this month expanded its team of C-suite executives, naming Todd Bazemore as chief operating officer. Bazemore has spent more than 20 years in the biopharmaceutical industry, most recently working as EVP and COO for Santhera Pharmaceuticals. He has also spent time at Dyax Corp., Sunovion Pharmaceuticals, and Muro Pharmaceuticals. “We welcome Todd to […]
Dexcom, Lilly ink deal to combine CGM into smart insulin delivery device
Dexcom (NSDQ:DXCM) said today that it inked a development deal with Eli Lilly (NYSE:LLY) to include its continuous glucose monitor in the insulin-maker’s connected delivery devices. The pair plans to start clinical trials by the end of this year, adding that they hope to position the combination of their technologies as a comprehensive solution for people with […]
Earnings round-up: Biogen, Lilly & Novartis post Street-beating Q3 results
When Johnson & Johnson posted its third quarter financial results last week, the healthcare giant credited its revenue growth to the strength of its pharmaceutical business. Three more pharmaceutical companies posted their Q3 results today, topping revenue and earnings estimates from analysts. Here’s a round-up of Q3 earnings from Biogen (NSDQ:BIIB), Eli Lilly (NYSE:LLY) and Novartis (NYSE:NVS). Biogen […]
Lilly invests $72m in insulin manufacturing facility
Eli Lilly (NYSE:LLY) plans to invest $72 million in its Indianapolis-based insulin manufacturing facility, the company said today. The funds will be used to replace an existing insulin vial filling line, according to Lilly. The company said it plans to spend more money in the U.S., as long as the Trump administration moves forward with […]
Here’s how the diabetes industry’s leaders think about patient-centered R&D
Designing devices centered around patients is a goal espoused by nearly all device companies nowadays, as they aim to make products that people want to use and can incorporate into their everyday lives. Underscoring those products is often years of research and some in the industry have begun to think about how a patient’s needs […]
Eli Lilly’s Humalog Junior KwikPen diabetes drug-device combo launches in U.S.
Eli Lilly‘s (NYSE:LLY) Humalog Junior KwikPen insulin lispro injection is available in the U.S. by prescription for people with diabetes, the company said today. The drug-device combination product is designed as a pre-filled, disposable half-unit insulin pen. The Humalog Junior KwikPen won FDA approval in June this year and earlier last month, a European Medicines […]
Convenience, compliance & control: How Insulet is changing insulin delivery tech
Shacey Petrovic spent nearly a decade trying to convince her diabetic father to switch to an insulin pump, rather than inject himself multiple times each day. But he was wary of the tubing and other challenges that come with constantly wearing a pump. So when Petrovic was tapped to serve as chief commercial officer at Insulet (NSDQ:PODD) in […]
Boehringer Ingelheim’s Jardiance cuts risk of cardiovascular death in T2D patients
Boehringer Ingelheim and Eli Lilly (NYSE:LLY) touted post-hoc analyses today showing that Jardiance reduced the risk of cardiovascular death in people with Type II diabetes and established cardiovascular disease, independent of blood sugar control at the start of the study. The companies also reported a reduced risk in cardiovascular death when Jardiance was added to first […]